- AU$310.77m
- AU$276.48m
- AU$3.42m
Brief: Racura Oncology Says Emerging Companies Specialist Invests In Racura
Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
Australia's Racura Oncology gains on Purdue University cancer study collab
Brief: Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220
Brief: Race Oncology Completes A$3.22 Mln Private Placement
Australia's Race Oncology advances on premium placement
Australia's Race Oncology rises after S.Korea approves tumor drug for clinical trials
Brief: Race Oncology Obtains RC220 IND Approval From Korean MFDS
Australia's Race Oncology rises on drug breakthrough; set for record best week
Australia's Race Oncology hits over two-year high on drug breakthrough, patent applications
Australia's Race Oncology jumps on progress in Phase 1 cancer drug trial
Brief: Race Oncology Reports Termination Of City Of Hope Global Ip License
Brief: Race Oncology Executes A$8.6M Contract
Brief: Race Oncology Appoints Pete Smith As Executive Chair
Brief: Race Oncology Posts FY Prelim Net Loss Attributable Of A$13.8 Mln
Brief: Race Oncology Says Appointment Of Contract Research Organisation
Australia's Race Oncology rises on FDA designation for leukaemia drug product
Brief: Race Oncology Says US FDA Rare Paediatric Disease Designation Granted
Brief: Race Oncology Says US FDA Orphan Drug Designation Awarded To RC220 Bisantrene